Castle Biosciences, Inc. (CSTL) Revenue History
Annual and quarterly revenue from 2017 to present
CSTL Revenue Over Time (2017–2025)
CSTL Revenue Growth History
8 of 8 years with positive growth- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- +65.7%
- FY2019 revenue growth
- +127.6%
- FY2020 revenue growth
- +20.8%
- FY2021 revenue growth
- +50.2%
- FY2022 revenue growth
- +45.7%
- FY2023 revenue growth
- +60.4%
- FY2024 revenue growth
- +51.1%
- FY2025 revenue growth
- +3.7%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $83.7M | -4.9% |
| Q4 2025 | $87.0M | +0.8% |
| Q3 2025 | $83.0M | -3.2% |
| Q2 2025 | $86.2M | -0.9% |
| Q1 2025 | $88.0M | +20.6% |
| Q4 2024 | $86.3M | +30.5% |
| Q3 2024 | $85.8M | +39.5% |
| Q2 2024 | $87.0M | +73.5% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2025)
CSTL's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
CSTL Revenue Analysis (2017–2025)
Current Revenue & Growth
As of June 23, 2026, Castle Biosciences, Inc. (CSTL) generated trailing twelve-month (TTM) revenue of $339.9 million, reflecting slight decline in growth of -4.9% year-over-year. The most recent quarter (Q1 2026) recorded $83.7 million in revenue, down 3.8% sequentially.
Historical Growth Trajectory
CSTL's 5-year compound annual growth rate (CAGR) stands at +40.6%, indicating outstanding long-term growth trajectory. The 3-year CAGR of +35.9% is below the 5-year average, signalling a growth deceleration in recent years. Castle Biosciences, Inc.'s highest annual revenue of $344.2 million was recorded in 2025, an all-time high.
Revenue by Segment
CSTL's revenue is primarily driven by Dermatologic (100%). With over half of revenue concentrated in Dermatologic, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including NTRA (+36.6% YoY), EXAS (+17.7% YoY), and VCYT (+16.9% YoY) — CSTL has underperformed the peer group in revenue growth. Compare CSTL vs NTRA →
CSTL Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CSTLCurrent | $340M | -4.9% | +40.6% | -12.4% | |
 NTRA | $2.3B | +36.6% | +42.6% | -13.4% | |
 EXAS | $3.2B | +17.7% | +16.8% | -6.4% | |
 VCYT | $517M | +16.9% | +34.5% | 14.3% | |
 ARDX | $407M | +18.2% | +121.9% | -10.1% | |
 FLGT | $323M | +13.8% | -5.2% | -28.2% |
CSTL Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $344.2M | +3.7% | $273.2M | 79.4% | $-42,810,000 | -12.4% |
| 2024 | $332.1M | +51.1% | $271.9M | 81.9% | $8.7M | 2.6% |
| 2023 | $219.8M | +60.4% | $174.8M | 79.5% | $-67,977,000 | -30.9% |
| 2022 | $137.0M | +45.7% | $105.0M | 76.6% | $-72,855,000 | -53.2% |
| 2021 | $94.1M | +50.2% | $78.3M | 83.2% | $-40,079,000 | -42.6% |
| 2020 | $62.6M | +20.8% | $53.0M | 84.5% | $-6,542,000 | -10.4% |
| 2019 | $51.9M | +127.6% | $44.6M | 85.9% | $7.3M | 14.1% |
| 2018 | $22.8M | +65.7% | $17.5M | 76.8% | $-3,835,643 | -16.8% |
| 2017 | $13.8M | - | $8.8M | 64.2% | $-10,899,676 | -79.2% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CSTL — Frequently Asked Questions
Quick answers to the most common questions about buying CSTL stock.
Is CSTL's revenue growth accelerating or slowing?
CSTL revenue growth is slowing. TTM revenue is $340M, up -4.9% year-over-year — below the 5-year CAGR of +40.6%. The deceleration suggests maturing end-markets or increased competition.
What is CSTL's revenue history from 2017 to 2026?
Castle Biosciences, Inc. (CSTL) revenue history spans 2017 to 2026. TTM revenue as of 2026 is $340M, growing at -4.9% YoY. The 5-year CAGR is +40.6%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is CSTL's long-term revenue growth rate (CAGR)?
Castle Biosciences, Inc.'s 5-year revenue CAGR of +40.6% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -4.9% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for CSTL.
Why does CSTL's quarterly revenue fluctuate?
CSTL quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Castle Biosciences, Inc.'s revenue data from 2017 to 2026 shows full historical quarterly detail on this page.
How is CSTL's revenue distributed by segment?
CSTL reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does CSTL's revenue compare to industry peers?
Castle Biosciences, Inc. (CSTL) with TTM revenue of $340M and -4.9% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.